

**Product Name** : BMS-509744

PD 0332991 **Synonyms** 

Cat No. M21885

**CAS Number** 439575-02-7

Molecular Formula : C24H29N7O2

Formula Weight : 447.53

**Chemical Name** 

BMS-509744 reduces T-cell receptor-induced functions including PLCy1 tyrosine phosphorylation, calcium mobilization, IL-2 secretion, and T-cell proliferation in vitro in both human and mouse cells. BMS-488516 and BMS-509744 potently inhibit Itk Description

in vitro with IC50 values of 96 and 19 nM, respectively. Both compounds exhibit competitive kinetics with respect to ATP,

suggesting that they bind to the ATP binding site of the ltk kinase domain.

**Pathway** : Angiogenesis

: CDK **Target** 

Receptor : MAPK/DYRK1A

: DMSO: 5 mg/mL (11.17 mM; ultrasonic and adjust pH to 3 with HCl); H2O: 0.1 mg/mL (0.22 mM; Need ultrasonic) Solubility

O=C1C(C(C)=O)=C(C2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(N5CCNCC5)C=N4)C **SMILES** 

: (-20℃) Storage

Stability : ≥2 years

Reference

1. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. 2. Katsumi Y, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun, 2011, 413(1), 62-68. 3. Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475.